Want to see TSE:BNXT full AI Analyst Report?
BNXT Stock Chart & Stats
C$0.33
C$0.01(3.33%)
At close: 4:00 PM EDT
C$0.33
C$0.01(3.33%)
Day’s Range― - ―
52-Week RangeC$0.28 - C$0.91
Previous CloseN/A
Volume17.35K
Average Volume (3M)31.12K
Market Cap
C$53.08M
Enterprise ValueC$49.67
Total Cash (Recent Filing)C$1.20M
Total Debt (Recent Filing)C$6.69M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding136,093,150
10 Day Avg. Volume39,280
30 Day Avg. Volume31,118
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnThe slower operating cash burn is a modest improvement in financial execution and could extend funding runway if maintained. However, cash generation remains negative, so this benefit is best viewed as an early efficiency improvement rather than evidence that the business is self-funding.
Higher Asset BaseAn increase in total assets provides some support for the company’s operating and financing base compared with the prior year. If sustained, a larger asset base could improve flexibility, although the benefit remains limited because debt materially exceeds assets and equity is negative.
Reported EPS ImprovementReported positive EPS growth indicates some year-over-year improvement in per-share earnings metrics despite the company remaining unprofitable. Continued improvement could eventually support a stronger earnings profile, but its durability is unproven while revenue is near zero and losses remain substantial.
Bears Say
Revenue CollapseThe collapse to effectively zero revenue leaves the company without a meaningful operating base to absorb costs or finance development. This creates a durable execution challenge: restoring commercial traction is essential before scale, recurring cash generation, or sustainable profitability can emerge.
Persistent Large LossesLarge and persistent losses demonstrate that the current business run-rate is not covering operating costs, especially with revenue effectively absent. Continued losses can consume capital, increase reliance on financing, and make any future path to profitability dependent on a material improvement in operations.
Stressed CapitalizationDebt materially exceeding assets and sustained negative equity indicate limited balance-sheet flexibility and a stressed capitalization structure. This raises ongoing dependence on external funding and leaves less capacity to absorb setbacks or invest in growth without further financing.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.28 and its highest was C$0.91 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$53.08M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Nov 27, 2026 which is in 70 days.
How were BioNxt Solutions’s earnings last quarter?
BioNxt Solutions released its earnings results on Aug 28, 2026. The company reported -C$0.009 earnings per share for the quarter.
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 136,093,150 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
BioNxt Solutions reported an EPS of -C$0.009 in its last earnings report. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.